CTOs on the Move

Harpoon Therapeutics

www.harpoontx.com

 
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.harpoontx.com
  • 611 Gateway Boulevard Suite 400
    South San Francisco, CA USA 94080
  • Phone: 650.443.7400

Executives

Name Title Contact Details

Funding

Harpoon Therapeutics raised $45M on 05/25/2017
Harpoon Therapeutics raised $70M on 11/12/2018

Similar Companies

SJ Pharmaceuticals

SJ Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Shenzhen Hepalink Pharmaceutical Co.

Hepalink was established in 1998 and restructured in 2007 to be a limited liability company.

Concerto HealthAI

Concerto HealthAI is a global leader in real-world data, AI technology, and real-world evidence services for precision oncology and dedicated to engineering integrated data and technology solutions that help achieve the best possible outcomes for patients.

Javan Engineering Inc

Javan Engineering Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.